Silver Grove Financial Group’s Dr. Reddy's Laboratories RDY Stock Holding History

Silver Grove Financial Group’s Portfolio RDY Stock Details RDY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.2K	Buy	+704	New	+$9.5K	0.01%	885

Other funds holding RDY

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

AIM

Aikya Investment Management London, United Kingdom $341M AUM 28.74% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Silver Grove Financial Group's RDY Position: Q2 2026 in Review

Silver Grove Financial Group opened a new position in Dr. Reddy's Laboratories (RDY) in Q2 2026: 704 shares worth $10.2K. The stake represents 0.01% of the portfolio and ranks #885 among its holdings.

238 funds tracked by Wall St. Rank hold RDY as of Q2 2026.

Silver Grove Financial Group held 704 shares of Dr. Reddy's Laboratories worth $10.2K as of Q2 2026.
Dr. Reddy's Laboratories was a new Silver Grove Financial Group position in Q2 2026.
Dr. Reddy's Laboratories made up 0.01% of Silver Grove Financial Group's portfolio in Q2 2026, its #885 holding.
238 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q2 2026.

Based on Silver Grove Financial Group's 13F filing for Q2 2026, filed 13 Aug 2026.